Cannabis-based medicines in multiple sclerosis - A review of clinical studies

Immunobiology

Volumn 215, Issue 8, 2010, Pages 658-672

  Rog, David J ^a  

^a Greater Manchester Neurosciences Centre   (United Kingdom)

Author keywords

Cannabinoids; Cannabis based medicines; Clinical trials; Multiple sclerosis; Sativex

Indexed keywords

CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; DIHYDROCODEINE; DRONABINOL; MORPHINE; NABILONE; NALOXONE; OPIATE ANTAGONIST; PLACEBO; TETRAHYDROCANNABINOL; TETRAHYDROCANNABINOLIC ACID;

AGITATION; ANKLE INJURY; ANOREXIA; ANXIETY; ARTICLE; ASPIRATION PNEUMONIA; BALANCE DISORDER; CLINICAL RESEARCH; CLINICAL TRIAL; DIARRHEA; DISEASE MODEL; DIZZINESS; DRUG FATALITY; DRUG WITHDRAWAL; FACE EDEMA; FATIGUE; HALLUCINATION; HEADACHE; HEART VENTRICLE BIGEMINY; HUMAN; MENTAL DISEASE; MOUTH DISCOMFORT; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; PAIN; POSTOPERATIVE PAIN; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SHOCK; SIDE EFFECT; SPEECH DISORDER; UNPLEASANT PSYCHOLOGICAL EFFECT; UNSPECIFIED SIDE EFFECT; VOMITING; WEAKNESS; PHYTOTHERAPY; REVIEW;

CANNABINOIDS; CANNABIS; HUMANS; MULTIPLE SCLEROSIS; PHYTOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77954177297     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2010.03.009     Document Type: Article

References (124)

1. Agurell S., Halldin M., Lindgren J.E., Ohlsson A., Widman M., Gillespie H., Hollister L. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacological Review 1986, 38:21-43.
2. Alger B.E., Pitler T.A. Retrograde signaling at GABAA-receptor synapses in the mammalian CNS. Trends in Neurosciences 1995, 18:333-340.
3. Ambler Z., Davies P. 2009. A two-phase study of Sativex® in the relief of spasticity due to multiple sclerosis: phase A single-blind response assessment followed by phase B double-blind, randomised, Placebo-controlled, parallel-group study. In: Proceedings of the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
4. Attal N., Cruccu G., Haanpaa M., Hansson P., Jensen T.S., Nurmikko T., Sampaio C., Sindrup S., Wiffen P. EFNS guidelines on pharmacological treatment of neuropathic pain. European Journal of Neurology 2006, 13:1153-1169.
5. Baker D., Pryce G., Giovannoni G., Thompson A.J. The therapeutic potential of cannabis. Lancet Neurology 2003, 2:291-298.
6. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Huffman J.W., Layward L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000, 404:84-87.
7. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Makriyannis A., Khanolkar A., Layward L., Fezza F., Bisogno T., Di Marzo V. Endocannabinoids control spasticity in a multiple sclerosis model. Journal of the Federation of American Societies for Experimental Biology 2001, 15:300-302.
8. Baker P.B., Gough T.A., Taylor B.J. The physical and chemical features of Cannabis plants grown in the United Kingdom of Great Britain and Northern Ireland from seeds of known origin - Part II: second generation studies. Bulletin on Narcotics 1983, 35:51-62.
9. Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Canadian Journal of Anesthesia 2006, 53:769-775.
10. Bisogno T., Berrendero F., Ambrosino G., Cebeira M., Ramos J.A., Fernandez-Ruiz J.J., Di Marzo V. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochemical and Biophysical Research Communications 1999, 256:377-380.
11. Booth M. Cannabis: A History 2003, Random House, London.
12. Bornheim L.M., Kim K.Y., Li J., Perotti B.Y., Benet L.Z. Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metabolism and Disposition 1995, 23:825-831.
13. Breivik E.K., Bjornsson G.A., Skovlund E. A comparison of pain rating scales by sampling from clinical trial data. Clinical Journal of Pain 2000, 16:22-28.
14. Bridges D., Ahmad K., Rice A.S. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. British Journal of Pharmacology 2001, 133:586-594.
15. British Medical Association Therapeutic uses of cannabis 1997, Harwood Academic, Australia ; United Kingdon.
16. Browne R.G., Weissman A. Discriminative stimulus properties of delta 9-tetrahydrocannabinol: mechanistic studies. Journal of Clinical Pharmacology 1981, 21:227S-234S.
17. Chong M.S., Wolff K., Wise K., Tanton C., Winstock A., Silber E. Cannabis use in patients with multiple sclerosis. Multiple Sclerosis 2006, 12:646-651.
18. Clark A.J., Ware M.A., Yazer E., Murray T.J., Lynch M.E. Patterns of cannabis use among patients with multiple sclerosis. Neurology 2004, 62:2098-2100.
19. Clifford D.B. Tetrahydrocannabinol for tremor in multiple sclerosis. Annals of Neurology 1983, 13:669-671.
20. Clinical Neurology Reserach Group, 2009. CUPID. In. Exeter & Plymouth: CNRG.
21. Collin C., Duncombe P. 2006. Meta-analysis of the effects of Sativex® on spasticity associated with multiple sclerosis. In: Proceedings of the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2006). Madrid, Spain.
22. Collin C., Ambler Z., Kent R., McCalla R. 2006 A randomised controlled study of Sativex® in patients with symptoms of spasticity due to multiple sclerosis. In: Proceeding of the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2006). Madrid, Spain.
23. Collin C., Davies P., Mutiboko I.K., Ratcliffe S. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. European Journal of Neurology 2007, 14:290-296.
24. Consroe P., Musty R., Rein J., Tillery W., Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. European Neurology 1997, 38:44-48.
25. Constantinescu C.S., Sarantis N. (2006) Long-term open-label treatment with Sativex® in patients with Multiple Sclerosis. In: Proceeding of the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2006). Madrid, Spain.
26. Conte A., Bettolo C.M., Onesti E., Frasca V., Iacovelli E., Gilio F., Giacomelli E., Gabriele M., Aragona M., Tomassini V., Pantano P., Pozzilli C., Inghilleri M. Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis. European Journal of Pain 2009, 13:472-477.
27. Corchero J., Avila M.A., Fuentes J.A., Manzanares J. delta-9-Tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the rat. Life Sciences 1997, 61:39-43. PL.
28. Corey S. Recent developments in the therapeutic potential of cannabinoids. Puerto Rico Health Sciences Journal 2005, 24:19-26.
29. D'Souza D.C., Kosten T.R. Cannabinoid antagonists: a treatment in search of an illness. Archives of General Psychiatry 2001, 58:330-331.
30. Davies C., 1992. Drug dealers saved my wife from her MS hell. In: The Mail on Sunday.
31. de Ridder D., Constantinescu C.S., Fowler C., Kavia R., Sarantis N., 2006. Randomised controlled study of cannabis-based medicine (Sativex®) in patients suffering from multiple sclerosis associated detrusor overactivity. In: Proceeding of the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2006). Madrid, Spain.
32. Dewey W.L. Cannabinoid pharmacology. Pharmacological Reviews 1986, 38:151-178.
33. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994, 372:686-691.
34. Doyle C., 1992. High dry and happier. In: The Daily Telegraph.
35. Felder C.C., Nielsen A., Briley E.M., Palkovits M., Priller J., Axelrod J., Nguyen D.N., Richardson J.M., Riggin R.M., Koppel G.A., Paul S.M., Becker G.W. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Letters 1996, 393:231-235.
36. Ferriman A., 1993. Marihuana: The best medicine? In: The Times.
37. Finnerup N.B., Otto M., McQuay H.J., Jensen T.S., Sindrup S.H. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005, 118:289-305.
38. Fox P., Bain P.G., Glickman S., Carroll C., Zajicek J. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004, 62:1105-1109.
39. Frank B., Serpell M.G., Hughes J., Matthews J.N., Kapur D. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. British Medical Journal 2008, 336:199-201.
40. Freeman R.M., Adekanmi O., Waterfield M.R., Waterfield A.E., Wright D., Zajicek J. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). International Urogynecology Journal and Pelvic Floor Dysfunction 2006, 17:636-641.
41. Fuentes J.A., Ruiz-Gayo M., Manzanares J., Vela G., Reche I., Corchero J. Cannabinoids as potential new analgesics. Life Sciences 1999, 65:675-685.
42. Ghaffar O., Feinstein A. Multiple sclerosis and cannabis: a cognitive and psychiatric study. Neurology 2008, 71:164-169.
43. Giuffrida A., Beltramo M., Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. Journal of Experimental Therapeutics 2001, 298:7-14.
44. Gong J.P., Onaivi E.S., Ishiguro H., Liu Q.R., Tagliaferro P.A., Brusco A., Uhl G.R. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Research 2006, 1071:10-23.
45. Greenberg H.S., Werness S.A., Pugh J.E., Andrus R.O., Anderson D.J., Domino E.F. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clinical Pharmacology & Therapeutics 1994, 55:324-328.
46. Grinspoon L., Bakalar J.B. Marihuana, the Forbidden Medicine 1993, Yale University Press.
47. Grotenhermen F. [Some practice-relevant aspects of the pharmacokinetics of THC]. Forsch Komplementarmed 1999, 6(Suppl 3):37-39.
48. GWPharmaceuticals, 2001. Investigator Brochure - Cannabis based medicine extract sublingual formulations. In.
49. GWPharmaceuticals, 2005. Product monograph Sativex® 2005. In.
50. GWPharmaceuticals, 2009. GW Reports Highly statistically significant results in Sativex® Pivotal phase III study in MS spasticity. In.
51. Handscombe M., 1993. Cannabis: why doctors want it to be legal. In: The Independent.
52. Hawks R.L. The constituents of cannabis and the disposition and metabolism of cannabinoids. NIDA Research Monograph 1982, 42:125-137.
53. HealthCanada, 2007. Notice of Compliance with conditions. In.
54. Herzberg U., Eliav E., Bennett G.J., Kopin I.J. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neuroscience Letters 1997, 221:157-160.
55. Hine B., Friedman E., Torrelio M., Gershon S. Morphine-dependent rats: blockade of precipitated abstinence by tetrahydrocannabinol. Science 1975, 187:443-445.
56. Hodges C., 1992. Very alternative medicine. In: The Spectator.
57. Hodges C., 1993. I wish I could get it at the chemist's. In: The Independent.
58. Hohmann A.G., Suplita R.L. Endocannabinoid mechanisms of pain modulation. AAPS Journal 2006, 8:E693-E708.
59. HouseofLords Cannabis: the scientific and medical evidence 1998, Stationery Office: House of Lords Committee on Science and Technology, London.
60. Howlett A.C., Johnson M.R., Melvin L.S., Milne G.M. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. Molecular Pharmacology 1988, 33:297-302.
61. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., Pertwee R.G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacology Reviews 2002, 54:161-202.
62. Ibrahim M.M., Porreca F., Lai J., Albrecht P.J., Rice F.L., Khodorova A., Davar G., Makriyannis A., Vanderah T.W., Mata H.P., Malan T.P. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proceedings of the National Academy of Sciences USA 2005, 102:3093-3098.
63. Iversen L. Cannabis and the brain. Brain 2003, 126:1252-1270.
64. Jackson S.J., Diemel L.T., Pryce G., Baker D. Cannabinoids and neuroprotection in CNS inflammatory disease. Journal of the Neurological Sciences 2005, 233:21-25.
65. Jackson S.J., Pryce G., Diemel L.T., Cuzner M.L., Baker D. Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation. Neuroscience 2005, 134:261-268.
66. James T., 1993. Breaking the law to beat MS. In: The Yorkshire Post.
67. Jhaveri M.D., Richardson D., Kendall D.A., Barrett D.A., Chapman V. Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. Journal of Neuroscience 2006, 26:13318-13327.
68. Johnson S.C., Saykin A.J., Flashman L.A., McAllister T.W., Sparling M.B. Brain activation on fMRI and verbal memory ability: functional neuroanatomic correlates of CVLT performance. Journal of the International Neuropsychological Society 2001, 7:55-62.
69. Karst M., Salim K., Burstein S., Conrad I., Hoy L., Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. Journal of the American Medical Association 2003, 290:1757-1762.
70. Kaymakcalan S., Ayhan I.H., Tulunay F.C. Naloxone-induced or postwithdrawal abstinence signs in delta9-tetrahydrocannabinol-tolerant rats. Psychopharmacology (Berl) 1977, 55:243-249.
71. Killestein J., Hoogervorst E.L., Reif M., Kalkers N.F., Van Loenen A.C., Staats P.G., Gorter R.W., Uitdehaag B.M., Polman C.H. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002, 58:1404-1407.
72. Kubajewska I., Constantinescu C.S., 2009. Cannabinoids and experimental models of multiple sclerosis. Immunobiology. Sep 16. [Epub ahead of print].
73. Kumar A.M., Haney M., Becker T., Thompson M.L., Kream R.M., Miczek K. Effect of early exposure to delta-9-tetrahydrocannabinol on the levels of opioid peptides, gonadotropin-releasing hormone and substance P in the adult male rat brain. Brain Research 1990, 525:78-83.
74. Kumar R.N., Chambers W.A., Pertwee R.G. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia 2001, 56:1059-1068.
75. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
76. Langdon D., 2003. The effect of cannabinoids on psychological factors in MS. In: Rehabilitation in Multiple Sclerosis.
77. Ligresti A., Cascio M.G., Pryce G., Kulasegram S., Beletskaya I., De Petrocellis L., Saha B., Mahadevan A., Visintin C., Wiley J.L., Baker D., Martin B.R., Razdan R.K., Di Marzo V. New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis. British Journal of Pharmacology 2006, 147:83-91.
78. Lyman W.D., Sonett J.R., Brosnan C.F., Elkin R., Bornstein M.B. Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 1989, 23:73-81.
79. Martyn C.N., Illis L.S., Thom J. Nabilone in the treatment of multiple sclerosis. Lancet 1995, 345:579.
80. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
81. Mattes R.D., Shaw L.M., Edling-Owens J., Engelman K., Elsohly M.A. Bypassing the first-pass effect for the therapeutic use of cannabinoids. Pharmacology Biochemistry & Behavior 1993, 44:745-747.
82. Maurer M., Henn V., Dittrich A., Hofmann A. Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. European Archives of Psychiatry and Clinical Neuroscience 1990, 240:1-4.
83. McPartland J., Russo E. Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts. Journal of Cannabis Therapeutics 2001, 1:103-132.
84. Meinck H.M., Schonle P.W., Conrad B. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. Journal of Neurology 1989, 236:120-122.
85. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
86. Notcutt W., Davies P., 2009. Results of a randomised withdrawal study of subjects with spasticity due to multiple sclerosis who were receiving long term Sativex®. In: Proceddings of the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
87. Notcutt W., Price M., Miller R., Newport S., Phillips C., Simmons S., Sansom C. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34'N of 1' studies. Anaesthesia 2004, 59:440-452.
88. Notcutt W.G., Price M., Chapman G. Clinical experience with nabilone for chronic pain. Pharmaceutical Sciences 1997, 3:551-555.
89. Pertwee R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacology & Therapeutics 1997, 74:129-180.
90. Pertwee R.G. Prescribing Cannabinoids for Multiple Sclerosis: Current Issues. CNS Drugs 1999, 11:327-334.
91. Petro D.J., Ellenberger C. Treatment of human spasticity with delta 9-tetrahydrocannabinol. Journal of Clinical Pharmacology 1981, 21:413S-416S.
92. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. Journal of the American Medical Association 2006, 295:761-775.
93. Piomelli D., Beltramo M., Giuffrida A., Stella N. Endogenous cannabinoid signaling. Neurobiology of Disease 1998, 5:462-473.
94. Pryce G., Ahmed Z., Hankey D.J., Jackson S.J., Croxford J.L., Pocock J.M., Ledent C., Petzold A., Thompson A.J., Giovannoni G., Cuzner M.L., Baker D. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003, 126:2191-2202.
95. Rang H.P., Dale M.M. Pharmacology 1991, Churchill Livingstone. 2nd ed. Edition.
96. Rao S.M., Group.C.F.S. A manual for the brief repeatable battery of neuropsychological tests in multiple sclerosis 1990, National Multiple Sclerosis Society, New York.
97. Ratcliffe S., Metz L., Ambler Z., 2008. Efficacy results of a study of THC:CBD in central neuropathic pain due to multiple sclerosis. In: Proceeding of the 24th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2008). Montreal.
98. Richardson J.D., Kilo S., Hargreaves K.M. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 1998, 75:111-119.
99. Rog D.J., Nurmikko T.J., Young C.A. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clinical Therapeutics 2007, 29:2068-2079.
100. Rog D.J., Nurmikko T.J., Friede T., Young C.A. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005, 65:812-819.
101. Solaro C., Brichetto G., Battaglia M.A., Messmer Uccelli M., Mancardi G.L. Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study. Neurological Sciences 2005, 25:307-310.
102. Solowij N., Stephens R.S., Roffman R.A., Babor T., Kadden R., Miller M., Christiansen K., McRee B., Vendetti J. Cognitive functioning of long-term heavy cannabis users seeking treatment. Journal of the American Medical Association 2002, 287:1123-1131.
103. Svendsen K.B., Jensen T.S., Bach F.W. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. British Medical Journal 2004, 329:253.
104. Ungerleider J.T., Andyrsiak T., Fairbanks L., Ellison G.W., Myers L.W. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Advances in Alcoholism and Substance Abuse 1987, 7:39-50.
105. UnitedKingdomHomeOffice, 2006. Letter to GW Pharmaceuticals Ltd. On file. In.
106. Vaney C., Heinzel-Gutenbrunner M., Jobin P., Tschopp F., Gattlen B., Hagen U., et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Multiple Sclerosis 2004, 10:417-424.
107. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389-1397.
108. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., Stella N., Makriyannis A., Piomelli D., Davison J.S., Marnett L.J., Di Marzo V., Pittman Q.J., Patel K.D., Sharkey K.A. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310:329-332.
109. Vela G., Ruiz-Gayo M., Fuentes J.A. Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine. Neuropharmacology 1995, 34:665-668.
110. Vela G., Fuentes J.A., Bonnin A., Fernandez-Ruiz J., Ruiz-Gayo M. Perinatal exposure to delta 9-tetrahydrocannabinol (delta 9-THC) leads to changes in opioid-related behavioral patterns in rats. Brain Research 1995, 680:142-147.
111. Wade D.T., Robson P., House H., Makela P., Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clinical Rehabilitation 2003, 17:21-29.
112. Wade D.T., Makela P., Robson P., House H., Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Multiple Sclerosis 2004, 10:434-441.
113. Wade D.T., Makela P.M., House H., Bateman C., Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Multiple Sclerosis 2006, 12:639-645.
114. Walker J.M., Huang S.M. Cannabinoid analgesia. Pharmacology & Therapeutics 2002, 95:127-135.
115. Whittle B., Guy G., Robson P.R. Prospects for new cannabis-based prescription medicines. Journal of Cannabis Therapeutics 2001, 1:183-205.
116. Willer J.C. Comparative study of perceived pain and nociceptive flexion reflex in man. Pain 1977, 3:69-80.
117. Wilsey B., Marcotte T., Tsodikov A., Millman J., Bentley H., Gouaux B., Fishman S. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. Journal of Pain 2008, 9:506-521.
118. Wilson R.I., Nicoll R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001, 410:588-592.
119. Wirguin I., Mechoulam R., Breuer A., Schezen E., Weidenfeld J., Brenner T. Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology 1994, 28:209-214.
120. Wissel J., Haydn T., Muller J., Brenneis C., Berger T., Poewe W., Schelosky L.D. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. Journal of Neurology 2006, 253:1337-1341.
121. You H.J., Dahl Morch C., Chen J., Arendt-Nielsen L. Simultaneous recordings of wind-up of paired spinal dorsal horn nociceptive neuron and nociceptive flexion reflex in rats. Brain Research 2003, 960:235-245.
122. Zajicek J., Reif M., Schnelle M., 2009. Cannabis extract in the treatment of muscle stiffness and other symptoms in multiple sclerosis - results of the MUSEC study. In: Proceeding of the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
123. Zajicek J., Fox P., Sanders H., Wright D., Vickery J., Nunn A., Thompson A. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003, 362:1517-1526.
124. Zajicek J.P., Sanders H.P., Wright D.E., Vickery P.J., Ingram W.M., Reilly S.M., Nunn A.J., Teare L.J., Fox P.J., Thompson A.J. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. Journal of Neurology, Neurosurgery and Psychiatry 2005, 76:1664-1669.